ImmunityBio's sBLA for Anktiva was unexpectedly rejected by the FDA, contradicting prior positive feedback and approval for a ...

ImmunityBio, Inc.’s IBRX share price has surged by 10.14%, which has investors questioning if this is right time to sell.

ImmunityBio (IBRX) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.12. This compares to loss of $0.20 per share a year ago. These figures are ...

ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced that the Company received a Refusal to ...

Shares of ImmunityBio Inc. grew as much as 18.8 percent at intraday trading before ending the day just up by 14.01 percent at ...

SAN DIEGO (AP) — SAN DIEGO (AP) — ImmunityBio, Inc. (IBRX) on Monday reported a loss of $129.6 million in its first quarter. On a per-share basis, the San Diego-based company said it had a loss of 15 ...

ImmunityBio received an RTF letter regarding a supplemental biologics license application it filed for the use of ANKTIVA ...

The Refusal to File letter comes despite the FDA’s prior encouragement to submit a supplemental biologics license application ...

ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced certain operational results following ...

SAN DIEGO (AP) — SAN DIEGO (AP) — ImmunityBio, Inc. (IBRX) on Monday reported a loss of $129.6 million in its first quarter. On a per-share basis, the San Diego-based company said it had a ...